Shandong Golden Empire Precision Machinery Technology Co., Ltd. (SHA:603270)
China · Delayed Price · Currency is CNY 27.18
+0.63 (2.37%)
At close: Aug 4, 2025, 2:57 PM CST
Inozyme Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
Net Income | 109.5 | 99.54 | 132.45 | 126.6 | 115.44 | 110.34 | Upgrade |
Depreciation & Amortization | 103.32 | 103.32 | 86.41 | 67.48 | 48.79 | 35.55 | Upgrade |
Other Amortization | 6.39 | 6.39 | 4.54 | 2.86 | 1.44 | 0.74 | Upgrade |
Loss (Gain) From Sale of Assets | 0.01 | 0.01 | 0.35 | -0.44 | 0.14 | 0.18 | Upgrade |
Asset Writedown & Restructuring Costs | 13.76 | 13.76 | 11.76 | 16.87 | 11.32 | 8.15 | Upgrade |
Loss (Gain) From Sale of Investments | -4.02 | -4.02 | 1.4 | -0.53 | -0.19 | -1.24 | Upgrade |
Stock-Based Compensation | - | - | - | - | 2.55 | 2.51 | Upgrade |
Provision & Write-off of Bad Debts | 16.09 | 16.09 | 2.53 | 4.81 | 3.28 | 3.43 | Upgrade |
Other Operating Activities | -9.58 | 4.37 | 15.92 | 14.8 | 16.49 | 19.17 | Upgrade |
Change in Accounts Receivable | -382.97 | -382.97 | -124.01 | -174.6 | -143.74 | -165.08 | Upgrade |
Change in Inventory | -100.24 | -100.24 | -70.16 | -58.6 | -110.41 | -17.94 | Upgrade |
Change in Accounts Payable | 90.48 | 90.48 | 42.75 | 69.99 | 96.68 | 69.11 | Upgrade |
Change in Other Net Operating Assets | 2.76 | 2.76 | 2.55 | 2.55 | - | - | Upgrade |
Operating Cash Flow | -162.03 | -158.04 | 100.95 | 58.42 | 44.93 | 68.07 | Upgrade |
Operating Cash Flow Growth | - | - | 72.82% | 30.02% | -33.99% | -65.65% | Upgrade |
Capital Expenditures | -558.86 | -460.76 | -126.32 | -209.28 | -154.5 | -80.35 | Upgrade |
Sale of Property, Plant & Equipment | 5.02 | 5.02 | 2.54 | 1.2 | 0.84 | 3.58 | Upgrade |
Investment in Securities | 236.9 | 217.9 | -447.9 | - | 23.91 | 34.29 | Upgrade |
Other Investing Activities | 6.71 | 7.04 | -3 | 0.53 | 0.35 | 1.08 | Upgrade |
Investing Cash Flow | -310.22 | -230.8 | -574.69 | -207.55 | -129.4 | -41.41 | Upgrade |
Long-Term Debt Issued | - | 359 | 408.83 | 314.23 | 344.15 | 332.27 | Upgrade |
Long-Term Debt Repaid | - | -178.12 | -588.59 | -210.27 | -360.28 | -368.08 | Upgrade |
Net Debt Issued (Repaid) | 446.93 | 180.88 | -179.76 | 103.96 | -16.13 | -35.8 | Upgrade |
Issuance of Common Stock | - | - | 1,117 | - | 215.37 | 31.9 | Upgrade |
Common Dividends Paid | -83.52 | -59.62 | -11.84 | -48.26 | -13.06 | -11.06 | Upgrade |
Other Financing Activities | -7.16 | -12.27 | -25.92 | - | - | - | Upgrade |
Financing Cash Flow | 356.25 | 108.99 | 899.45 | 55.7 | 186.18 | -14.96 | Upgrade |
Foreign Exchange Rate Adjustments | -2.43 | -4.92 | 0.96 | 3.47 | -1.3 | -0.63 | Upgrade |
Net Cash Flow | -118.43 | -284.76 | 426.67 | -89.96 | 100.41 | 11.07 | Upgrade |
Free Cash Flow | -720.89 | -618.8 | -25.37 | -150.86 | -109.57 | -12.29 | Upgrade |
Free Cash Flow Margin | -49.24% | -45.66% | -2.23% | -13.75% | -11.98% | -1.94% | Upgrade |
Free Cash Flow Per Share | -3.28 | -2.80 | -0.14 | -0.92 | -0.74 | -0.08 | Upgrade |
Cash Income Tax Paid | 58.88 | 56.12 | 65.28 | 56.63 | 57.93 | 34.39 | Upgrade |
Levered Free Cash Flow | -688.52 | -503.35 | -59.13 | -75.46 | -96.24 | -49.53 | Upgrade |
Unlevered Free Cash Flow | -683.49 | -499.2 | -49.96 | -63.17 | -86.26 | -37.7 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.